Bionomics to Present at 2024 ASCP Annual Meeting
May 20, 2024 -- Bionomics Limited, a biotechnology company listed on Nasdaq under the ticker BNOX, is engaged in developing innovative allosteric ion channel modulators aimed at treating severe central nervous system (CNS) disorders. The company has announced that its President and CEO, Dr. Spyridon “Spyros” Papapetropoulos, will deliver an oral presentation and two poster presentations on their lead drug candidate, BNC210, at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting. This event is scheduled to be held from May 28 to May 31 in Miami Beach, Florida.
Dr. Papapetropoulos will present findings on BNC210 as a potential treatment for social anxiety disorder (SAD) and post-traumatic stress disorder (PTSD). The details of the presentations are as follows:
1. Title: Positive Results Achieved in a Phase 2b, Double-Blind, Placebo-Controlled Study for BNC210, an Alpha7 Nicotinic Receptor Negative Allosteric Modulator, for the Treatment of PTSD (ATTUNE)
- Session: Pharmaceutical Pipeline
- Date and Time: Tuesday, May 28, from 2:40 to 2:50 PM ET
- Location: Loews Miami Beach Hotel, Salon 3
2. Title: A Phase 3, Double-Blind, Placebo-Controlled Study for BNC210, an Alpha7 Nicotinic Receptor Negative Allosteric Modulator, for the Acute Treatment of Anxiety in Social Anxiety Disorder (AFFIRM-1)
- Poster Session: I
- Date and Time: Wednesday, May 29, from 11:15 AM to 1:00 PM ET
- Location: Loews Miami Beach Hotel, Salon 4
3. Title: Positive Results Achieved in a Phase 2b, Double-Blind, Placebo-Controlled Study for BNC210, an Alpha7 Nicotinic Receptor Negative Allosteric Modulator, for the Treatment of PTSD (ATTUNE)
- Poster Session: II
- Date and Time: Thursday, May 30, from 12:30 to 2:15 PM ET
- Location: Loews Miami Beach Hotel, Salon 4
These poster presentations will be accessible on Bionomics’ website under the “Papers and Posters” page.
Bionomics Limited, which trades on NASDAQ as BNOX, is a clinical-stage biotechnology company developing novel, first-in-class drugs targeting CNS disorders with significant unmet needs. The company's primary focus is on BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor. This drug is being developed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD).
In addition to BNC210, Bionomics has a strategic partnership with Merck & Co., Inc., known as MSD outside the United States and Canada. This collaboration involves two drugs currently in early-stage clinical trials for treating cognitive deficits in Alzheimer’s disease and other CNS conditions. Bionomics’ pipeline also includes preclinical assets targeting Kv3.1/3.2 and Nav1.7/1.8 ion channels, which are being developed for various CNS conditions with high unmet needs.
Bionomics continues to advance its research and development in the quest to provide effective treatments for patients with serious CNS disorders. The company's participation in the ASCP Annual Meeting underscores its commitment to addressing these critical health challenges through innovative scientific approaches.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
